Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31410029 | 0.78 | PLAU (0.35) | PLAUDAO | |
| SCHEMBL31410006 | 0.78 | MAPT (0.33) | PLAULMNASMN1; SMN2MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL31409911 | 0.77 | PLAU (0.34) | PLAUDAO | |
| SCHEMBL31409915 | 0.76 | HTR5A (0.36) | LMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL19206187 | 0.73 | LMNA (0.36) | PLAULMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL31410031 | 0.72 | PLAU (0.42) | PLAULMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL31409944 | 0.71 | — | — | |
| SCHEMBL23850426 | 0.70 | NFKB1 (0.38) | SMN1; SMN2MAPTKMT2A | |
| SCHEMBL19206188 | 0.69 | SIRT6 (0.38) | MAPTKMT2A | |
| SCHEMBL2220883 | 0.66 | PLAU (0.39) | PLAUDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | BOEHRINGER INGELHEIM INT (DE) | 2025-03-27 | — | — | US | disclosed |
| WO-2025027049-A1 | (2S,5R)-5-(HYDROXYMETHYL)MORPHOLINE-2-CARBOXAMIDES AS AGONISTS OF SSTR4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | SSTR4, SSTR5, SSTR2 | PLAU 2989/4885LMNA 4084/4885SMN1; SMN2 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.